Post a Comment Print Share on Facebook
Featured BNG WiZink Irene Montero

Pfizer will sell its 32% stake in Haleon, the joint venture with GSK

MADRID, 1 Jun.

- 9 reads.

Pfizer will sell its 32% stake in Haleon, the joint venture with GSK

MADRID, 1 Jun. (EUROPA PRESS) -

The American pharmaceutical company Pfizer will completely sell its 32% stake in Haleon, the 'joint venture' that it formed with GSK, bringing together its non-prescription drug business ('consumer healthcare'), as reported in a statement on Wednesday.

The decision comes within the framework of the company's IPO, which GSK announced in June last year. This Wednesday, the British laboratory has indicated that Haleon will go public through a spin-off that will mean delivering 80% of the 68% stake in its shareholders.

Haleon will begin trading in London in July this year, but Pfizer's divestment will not be immediate. The company has indicated that it plans to exit the firm in a "disciplined" manner that maximizes shareholder value.

Following the delivery of 80% of its stake in Haleon to its own shareholders, GSK will retain a representation of approximately 13.6% in the company. In addition, the new listed company plans that its titles will be traded on the New York Stock Exchange under the figure of the American Depositary Shares (ADS).

Through this IPO, GSK will focus its business on biopharmaceuticals and investing in innovative vaccines and specialty medicines.

Keywords:
PfizerGSK